Get the Stockscreener App
17.09
0.70%
-0.12
After Hours:
17.09
Rigel Pharmaceuticals stock is traded at $17.09, with a volume of 405.66K.
It is down -0.70% in the last 24 hours and down -29.70% over the past month.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
See More
Previous Close:
$17.21
Open:
$16.85
24h Volume:
405.66K
Relative Volume:
1.81
Market Cap:
$301.04M
Revenue:
$116.88M
Net Income/Loss:
$-25.09M
P/E Ratio:
-77.68
EPS:
-0.22
Net Cash Flow:
$-20.74M
1W Performance:
-9.62%
1M Performance:
-29.70%
6M Performance:
+78.92%
1Y Performance:
+38.94%
1-Day Range:
$16.85
$17.76
1-Week Range:
$16.68
$19.80
52-Week Range:
$7.4843
$29.82
Rigel Pharmaceuticals Stock (RIGL) Company Profile
Name
Rigel Pharmaceuticals
Sector
Industry
Phone
650-624-1100
Address
611 GATEWAY BOULEVARD, SUITE 900, SOUTH SAN FRANCISCO, CA
Compare RIGL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RIGL
Rigel Pharmaceuticals
|
17.09 | 301.04M | 116.88M | -25.09M | -20.74M | -0.14 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Rigel Pharmaceuticals Stock (RIGL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-03-23 | Resumed | Piper Sandler | Neutral |
| Jun-09-22 | Downgrade | Citigroup | Buy → Neutral |
| Jun-08-22 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jun-08-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Mar-23-22 | Initiated | B. Riley Securities | Neutral |
| Nov-09-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-15-19 | Resumed | Cantor Fitzgerald | Overweight |
| Sep-26-19 | Resumed | JP Morgan | Overweight |
| Mar-01-19 | Reiterated | Cantor Fitzgerald | Overweight |
| Aug-27-18 | Initiated | Citigroup | Buy |
| May-02-18 | Reiterated | Cantor Fitzgerald | Overweight |
| Dec-21-17 | Resumed | Piper Jaffray | Overweight |
| Dec-15-17 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-06-17 | Resumed | H.C. Wainwright | Buy |
| Mar-09-17 | Reiterated | H.C. Wainwright | Buy |
| Aug-31-16 | Reiterated | H.C. Wainwright | Buy |
| Aug-30-16 | Reiterated | Piper Jaffray | Overweight |
| Jul-13-16 | Initiated | H.C. Wainwright | Buy |
| Jun-13-16 | Initiated | Piper Jaffray | Overweight |
| Apr-22-16 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-08-13 | Reiterated | Stifel | Buy |
| Nov-29-12 | Initiated | UBS | Neutral |
| Nov-06-12 | Reiterated | Oppenheimer | Outperform |
| Mar-26-12 | Initiated | Canaccord Genuity | Hold |
| Dec-10-10 | Downgrade | MP Advisors | Outperform → Market Perform |
View All
Rigel Pharmaceuticals Stock (RIGL) Latest News
Lacklustre Performance Is Driving Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) 28% Price Drop - Simply Wall St
Rigel to Present at the Jefferies London Healthcare Conference - The Eastern Progress Online
(RIGL) Trading Signals - Stock Traders Daily
Rigel Pharmaceuticals' SWOT analysis: stock poised for growth amid challenges - Investing.com Australia
Recent 26% pullback isn't enough to hurt long-term Rigel Pharmaceuticals (NASDAQ:RIGL) shareholders, they're still up 50% over 1 year - Yahoo Finance
Thérapeutique Knight annonce l’approbation réglementaire de TAVALISSE® au Mexique - GlobeNewswire Inc.
Rigel Pharmaceuticals (NASDAQ:RIGL) shareholders are still up 50% over 1 year despite pulling back 26% in the past week - Simply Wall St
Immune Thrombocytopenia Purpura Market to Expand Significantly by 2034, States DelveInsight Report | Biotest, Argenx, Sanofi, Principia Biopharma, Rigel Pharma, Principia Biopharma, GlaxoSmithKline - The Globe and Mail
Rigel to Present at the 2024 Cantor Global Healthcare Conference - The Eastern Progress Online
Rigel Highlights Initial Data from Ongoing Phase 1b Study Evaluating R289 in LR-MDS at the 66th ASH Annual Meeting and Exposition - The Malaysian Reserve
Rigel Pharmaceuticals (NASDAQ:RIGL) Given "Buy" Rating at HC Wainwright - MarketBeat
Rigel Pharmaceuticals announces initial data from Phase 1b study of R289 - TipRanks
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
(RIGL) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Jacobs Levy Equity Management Inc. Has $2.87 Million Stake in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) - MarketBeat
B. Riley Forecasts Strong Price Appreciation for Rigel Pharmaceuticals (NASDAQ:RIGL) Stock - MarketBeat
Rigel Pharmaceuticals, Inc. Appoints Keith A. Katkin to its Board of Directors - Marketscreener.com
PDT Partners LLC Purchases New Holdings in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) - MarketBeat
Rigel Pharmaceuticals announces R289 granted Fast Track designation by FDA - TipRanks
Rigel Announces R289 Granted Fast Track Designation by the FDA for Lower-Risk MDS - PR Newswire
Rigel Pharma's Blood Disorder Drug R289 Wins FDA Fast Track Status for MDS Treatment - StockTitan
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Sees Significant Decline in Short Interest - MarketBeat
How To Trade (RIGL) - Stock Traders Daily
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Shares Purchased by Connor Clark & Lunn Investment Management Ltd. - MarketBeat
SEC Form 4 filed by CEO, President Rodriguez Raul R - Quantisnow
Warm Autoimmune Hemolytic Anemia Market to Observe Stupendous Growth During the Forecast Period (2020-2034) | Rigel Pharmaceuticals, Bioverativ (Sanofi), Incyte, Johnson & Johnson - The Globe and Mail
Rigel Pharmaceuticals, Inc. Appoints Dean Schorno as Executive Vice President and Chief Financial Officer - Marketscreener.com
Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - GuruFocus.com
Rigel Pharmaceuticals : Announces Conference Call and Webcast to Report First Quarter 2020 Financial Results and Business Update - Marketscreener.com
How Much Upside is Left in Rigel (RIGL)? Wall Street Analysts Think 28.28% - MSN
Rigel Pharmaceuticals To Present At Jefferies London Healthcare Conference; Webcast At 4:30 AM ET - Nasdaq
(RIGL) Proactive Strategies - Stock Traders Daily
Exploring Three High Growth Tech Stocks in the United States - Simply Wall St
ARMISTICE CAPITAL, LLC Reduces Stake in Rigel Pharmaceuticals Inc - GuruFocus.com
Los Angeles Capital Management LLC Grows Stake in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) - MarketBeat
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Receives $33.38 Average PT from Analysts - MarketBeat
Rigel Pharmaceuticals price target raised to $23 from $15 at Piper Sandler - TipRanks
Rigel Pharmaceuticals (NASDAQ:RIGL) Price Target Raised to $23.00 at Piper Sandler - MarketBeat
Rigel Pharmaceuticals' SWOT analysis: stock shows promise amid challenges By Investing.com - Investing.com Australia
Rigel Pharmaceuticals price target raised to $49 from $40 at Citi - TipRanks
Rigel Pharmaceuticals' SWOT analysis: stock shows promise amid challenges - Investing.com
Citi raises Rigel Pharma stock target, buy rating on strong Gavreto sales - Investing.com
Biotech Alert: Searches spiking for these stocks today - TipRanks
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Q3 2024 Earnings Call Transcript - Insider Monkey
Rigel Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations - Simply Wall St
Rigel stock rallies 36% after Q3 earnings beat - MSN
Rigel Pharmaceuticals stock hits 52-week high at $17.5 By Investing.com - Investing.com Australia
Earnings call: Rigel Pharmaceuticals reports strong Q3 growth, plans expansion - Investing.com Canada
Rigel Pharmaceuticals Stock (RIGL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Rigel Pharmaceuticals Stock (RIGL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Santos David A | EVP, Chief Commercial Officer |
Feb 02 '24 |
Sale |
1.13 |
5,601 |
6,329 |
358,011 |
| Schorno Dean L | EVP & Chief Financial Officer |
Feb 05 '24 |
Sale |
1.14 |
7,027 |
8,011 |
402,891 |
| Schorno Dean L | EVP & Chief Financial Officer |
Feb 02 '24 |
Sale |
1.13 |
5,601 |
6,327 |
409,918 |
| RODRIGUEZ RAUL R | CEO, President |
Feb 05 '24 |
Sale |
1.14 |
30,545 |
34,821 |
2,036,629 |
| RODRIGUEZ RAUL R | CEO, President |
Feb 02 '24 |
Sale |
1.13 |
22,349 |
25,261 |
2,067,174 |
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):